AVADOMIDE
CC122
CAS: 1015474-32-4
Molecular Formula: C14H14N4O3
AVADOMIDE - Names and Identifiers
AVADOMIDE - Physico-chemical Properties
| Molecular Formula | C14H14N4O3 |
| Molar Mass | 286.29 |
| Density | 1.58±0.1 g/cm3(Predicted) |
| Melting Point | > 270°C (dec.) |
| Solubility | DMSO: ≥ 33 mg/mL |
| Appearance | Solid |
| Color | Pale Beige |
| pKa | 10.66±0.40(Predicted) |
| Storage Condition | Hygroscopic, -20°C Freezer, Under inert atmosphere |
| In vitro study | CC-122 is a new drug that responds to diffuse large B- cell lymphoma with antitumor and immunomodulatory activity. In DLBCL cell lines, it binds to and induces degradation of CEBN, or is involved in short hairpin RNA-mediated knockdown of Aiolos and Ikaros, which are associated with increased transcription of interferon IFN, it is independent of the production or secretion of IFN-α, -β and-γ, thereby leading to apoptosis of activated B cells and the B- cell DLBCL cell line of the germinal center. CRBN is a molecular target of CC-12, and CC-12 binds to CRBN, recruiting Aiolos/Ikaros to bind to crl4. |
| In vivo study | In the ABC-and GCB-DLBCL cell xenograft tumor model, CC-122 was able to reduce tumor growth and stimulate IL-2 production of primary T cells. In a single-arm clinical trial CC-122, administration CC-122 reduced the expression levels of Aiolos and Ikaros in patients by 25%-50%, and thus these two proteins could serve as pharmacodynamic markers CC-122. |
AVADOMIDE - Preparation solution concentration reference
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 3.493 ml | 17.465 ml | 34.93 ml |
| 5 mM | 0.699 ml | 3.493 ml | 6.986 ml |
| 10 mM | 0.349 ml | 1.747 ml | 3.493 ml |
| 5 mM | 0.07 ml | 0.349 ml | 0.699 ml |
Last Update：2024-01-02 23:10:35
AVADOMIDE - Reference Information
| biological activity | Avadomide (CC-122), a Novel pleiotropic modifier compound, in diffuse large B- cell lymphoma (DLBCL) with anti-tumor, immune regulation activity. Its molecular target is cereblon (CRBN), which is a substrate receptor for the E3 ubiquitinated ligase complex CRL4 CRBN. |
| Target | TargetValue CRBN () |
| Target | Value |
| in vitro study | CC-122 is a novel drug that responds to diffuse large B- cell lymphoma with antitumor and immunomodulatory activity. In DLBCL cell lines, it binds to and induces degradation of CEBN, or is involved in short hairpin RNA-mediated knockdown of Aiolos and Ikaros, which are associated with increased transcription of interferon IFN, it is independent of the production or secretion of IFN-α, -β and-γ, thereby leading to apoptosis of activated B cells and the B- cell DLBCL cell line of the germinal center. CRBN is a molecular target of CC-12, and CC-12 binds to CRBN, recruiting Aiolos/Ikaros to bind to crl4. |
| in vivo studies | in ABC-and GCB-DLBCL-cell xenograft tumor models, CC-122 reduced tumor growth, stimulation of IL-2 production of primary T cells. In a single-arm clinical trial CC-122, administration CC-122 reduced the expression levels of Aiolos and Ikaros in patients by 25%-50%, and thus these two proteins could serve as pharmacodynamic markers CC-122. |
Last Update：2024-04-09 19:05:05
Supplier List
Spot supply
Product Name: CC122 Visit Supplier Webpage Request for quotationCAS: 1015474-32-4
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Spot supply
Product Name: CC122 Visit Supplier Webpage Request for quotationCAS: 1015474-32-4
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History